Speakers

Expand/Collapse

Eduardo Bruno Martins
Chief Medical Officer
Sagimet Biosciences

Day Two

Thursday May 6 2021

11:00 am | Combination Therapy for HBV Cure

Yuchun Nie
Senior scientist
Aligos Therapeutics

Gaston Picchio
Chief Development Officer
Arbutus Biopharma

Day One

Wednesday May 5 2021

4:00 pm | An RNAi for the Treatment Of Chronic Hepatitis B Infection: Clinical Update

Jinzi Wu
Founder, Chairman and Chief Executive Officer
Ascletis Pharma

Day Two

Thursday May 6 2021

9:30 am | Strategy of Building HBV Pipeline Leading to Functional Cure

William Delaney
Chief Scientific Officer
Assembly Biosciences (USA)

Day Two

Thursday May 6 2021

12:30 pm | Targeting HBV Core Protein to Improve Treatment for Chronic Hepatitis B Patients

Stephane Daffis
Scientist II
Gilead Sciences

Day One

Wednesday May 5 2021

9:30 am | Keynote Presentation from Gilead Sciences: Preclinical Development of Toll-like Receptor Agonists for Chronic HBV Infection

Yong-Yuan Zhang
Founder and Chief Science Officer
HBVtech

Day One

Wednesday May 5 2021

10:00 am | Curing Chronic HBV Infection Guided by HBV Infection Biology

Melissa Palmer
Chief Medical Officer
Gannex, a Subsidiary of Ascletis Pharma

Day One

Wednesday May 5 2021

2:00 pm | Managing Potential Drug-Induced Liver Injuries During Clinical Trials for Novel HBV Therapies

Chari Cohen
Senior Vice President
Hepatitis B Foundation

Day Two

Thursday May 6 2021

2:30 pm | The Patient Perspective on Hepatitis B Treatment, Cure & Clinical Trial Participation

Paul Desmond
Coordinator
Hepatitis B Positive Trust

Day Two

Thursday May 6 2021

3:00 pm | Panel Discussion: Discuss How We Can Identify Patient Populations for a Variety of Chronic HBV Therapeutic Trials

2:00 pm | Global Barriers to a HBV Cure Roll-Out

Marco Lepore
Head of Discovery Research
Immunocore Ltd

Day One

Wednesday May 5 2021

3:30 pm | Immtav® Molecules for The Treatment Of Hepatitis B

Patricia Mendez
Vice President - Clinical Development
Immunocore Ltd

Day Two

Thursday May 6 2021

3:00 pm | Panel Discussion: Discuss How We Can Identify Patient Populations for a Variety of Chronic HBV Therapeutic Trials

Andrew Vaillant
Chief Scientific Officer
Replicor Inc.

Day Two

Thursday May 6 2021

12:00 pm | HBsAg, Subviral Particles and Their Clearance in Establishing Functional Cure of Chronic HBV Infection

David Anderson
Chief Scientific Officer
VBI Vaccines Inc.

Day Two

Thursday May 6 2021

10:00 am | Role of a Vaccine Immunotherapeutic in Combination Therapy to Achieve Functional Cure for Chronic HBV Infection

Stephan Urban
Professor
University Hospital of Heidelberg

Day One

Wednesday May 5 2021

11:30 am | Towards a Curative Therapy for Hepatitis B and D Co-Infected Patients: A Pivotal Role for Entry Inhibition with Myrcludex B/ Bulevirtide Alone or in Combination with Peg-IFN-alpha

Haitao Guo
Professor
University of Pittsburgh

Day One

Wednesday May 5 2021

12:00 pm | Harnessing New Knowledge of HBV Replication Cycle for Antiviral Discovery

Tom Evans
Chief Scientific Officer
Vaccitech

Day One

Wednesday May 5 2021

2:30 pm | Development of a Therapeutic Vaccine for Hepatitis B

Pietro Scalfaro
Chief Medical Officer
ENYO Pharma

Day Two

Thursday May 6 2021

9:00 am | Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B

Ventzislav Vassilev
Program Development Lead, Chronic Hepatitis B Immunotherapy
GSK

Day One

Wednesday May 5 2021

9:15 am | Opening Remarks from Chairperson

Day Two

Thursday May 6 2021

8:45 am | Opening Remarks from Chairperson

Philippe Zamor
Hepatology Consultant
Atrium Health

Day Two

Thursday May 6 2021

1:30 pm | Viral hepatitis and hepatocellular carcinoma: diagnosis, treatment and management

Scott Harris
Chief Medical Officer
Altimmune

Day One

Wednesday May 5 2021

1:30 pm | How we can achieve success with immunotherapeutics in the treatment of chronic hepatitis B